D-2570 Dose 3
Phase 2
D-2570 Dose 3 is one of 28 therapeutic programs targeting Vitiligo. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
34 competitors in Vitiligo
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Trexall
Jazz PharmaceuticalsApproved
Cosentyx
NovartisApproved
Xalatan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Asmanex
PPerrigo Company
Approved
Elidel
BBausch Health Americas, Inc.
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Adrucil
EElorac, Inc.
Approved
Rinvoq
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Vitiligo1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for D-2570 Dose 3. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- IInventisBio Co., Ltd